Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 2/20 | 0.61 |
| ▸ | THRB | P10828 | 3/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 9/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1014017 | 1.00 | PDE4B (0.61) | PDE4BTHRBRXFP1MAPTTP53 | |
| SCHEMBL1015071 | 0.94 | PDE4B (0.68) | PDE4BTHRBRXFP1MAPTTP53 | |
| SCHEMBL1015585 | 0.81 | RAB9A (0.53) | PDE4BMAPTRAB9A | |
| SCHEMBL1014628 | 0.81 | RAB9A (0.53) | PDE4BMAPTRAB9A | |
| SCHEMBL1014765 | 0.79 | RAB9A (0.51) | PDE4BMAPTPOLBRAB9A | |
| SCHEMBL1014054 | 0.79 | RAB9A (0.51) | PDE4BMAPTPOLBRAB9A | |
| SCHEMBL6016541 | 0.77 | THRB (0.66) | THRBRXFP1MAPTTP53POLB | |
| SCHEMBL22440422 | 0.76 | PDE4B (1.00) | PDE4BMAPTTP53 | |
| SCHEMBL1018338 | 0.76 | RAB9A (0.48) | PDE4BMAPTPOLBRAB9A | |
| SCHEMBL1015077 | 0.76 | RAB9A (0.48) | PDE4BMAPTPOLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2271629-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | AstraZeneca AB (SE) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009130496-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-29 | — | — | WO | disclosed |
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | CYP2S1, HSD11B1, HSD3B1 | PDE4B 474/4885THRB 1031/4885RXFP1 3075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.